Filing Details
- Accession Number:
- 0001127602-18-001216
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-01-04 19:54:59
- Reporting Period:
- 2018-01-02
- Accepted Time:
- 2018-01-04 19:54:59
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 882095 | Gilead Sciences Inc | GILD | Biological Products, (No Disgnostic Substances) (2836) | 943047598 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1190578 | C John Martin | Gilead Sciences, Inc. 333 Lakeside Drive Foster City CA 94404 | Executive Chairman | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-01-02 | 50,000 | $23.60 | 3,046,766 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-01-02 | 4,105 | $72.26 | 3,042,661 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-01-02 | 26,941 | $73.60 | 3,015,720 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-01-02 | 18,954 | $73.95 | 2,996,766 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-qualified Stock Option (Right to Buy) | Disposition | 2018-01-02 | 50,000 | $0.00 | 50,000 | $23.60 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 550,000 | 2019-01-21 | No | 4 | M | Direct |
Footnotes
- The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
- The options have a five year vesting schedule. 20% vest on the first anniversary of the date of grant. The balance will vest 5% quarterly thereafter until fully vested.
- Sale prices reported for the transactions reported here range from $71.74 to $72.73. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- Sale prices reported for the transactions reported here range from $72.79 to $73.79. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- Sale prices reported for the transactions reported here range from $73.80 to $74.21. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
Billionaire Hedge Funds
